Melane Sampson, Author at BioTuesdays

Executive Moves

Dr. Ingrid Müller joins Evotec as COO

Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT) has appointed Dr. Ingrid Müller as Chief Operating Officer (COO), effective May 1, 2026. Dr. Müller brings to the role more than 20 years of international leadership...

April 15, 2026

Developments

FDA grants Arbutus fast track designation for imdusiran in cHBV

Arbutus Biopharma (NASDAQ: ABUS) has announced that the FDA has granted fast track designation for imdusiran for the treatment of chronic hepatitis B (cHBV). Imdusiran is an RNAi therapeutic specifically designed to...

April 15, 2026

Developments

Stereotaxis to acquire Robocath

Stereotaxis (NYSE: STXS) has announced that it has entered into a definitive agreement to acquire closely held Robocath, a venture-backed innovator of robotic techniques for interventional cardiology and...

April 15, 2026

Developments

MHRA clears Poolbeg for cancer immunotherapy trial

Poolbeg Pharma (AIM: POLB; OTC: POLBF; FRA: POLBF) has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the company clinical trial authorization for its TOPICAL trial with...

April 15, 2026

Executive Moves

Prelude appoints Dr. Charles Morris as CMO

Prelude Therapeutics (NASDAQ: PRLD) has appointed Dr. Charles Morris as chief medical officer (CMO), effective April 20, 2026. Dr. Morris is a medical oncologist with more than 30 years of oncology drug development...

April 15, 2026

Developments

SIR highlights Profound’s CAPTAIN study results showing faster recovery with TULSA v robotic prostate surgery

The Society of Interventional Radiology (SIR) has highlighted the results of Profound Medical’s (NASDAQ: PROF; TSX: PRN) randomized post-market CAPTAIN trial demonstrating that men with localized, intermediate-risk...

April 14, 2026

Developments

Nature Medicine publishes Actuate’s data from trial of elraglusib + chemo in mPC

Actuate Therapeutics (NASDAQ: ACTU) has announced the publication of new data in Nature Medicine from its Phase 2 clinical trial evaluating elraglusib in combination with the gemcitabine-Nab-paclitaxel (GnP)...

April 14, 2026

Developments

Cellectar enrolls first patient in Phase 1b study of CLR 125 targeting TNBC

Cellectar Biosciences (NASDAQ: CLRB) has announced that the first patient has been enrolled in the Phase 1b trial of CLR 121125 (CLR 125) for the potential treatment of triple negative breast cancer (TNBC). According to...

April 14, 2026

Feature

MAIA Biotechnology aiming to extend lives through new cancer treatment class with telomere-targeting agent

MAIA Biotechnology (NYSE American: MAIA) is focusing on the development and commercialization of breakthrough telomere-targeting immunotherapies: potential first-in-class drugs with novel mechanisms of action that aim...

April 14, 2026

Developments

Firefly builds world’s first 200,000+ EEG/ERP brain scan depository

Firefly Neuroscience (NASDAQ: AIFF) has achieved a major operational and commercial milestone with more than 200,000 EEG/ERP (human brain function) scans. Through its acquisition of Evoke Neuroscience in May 2025...

April 13, 2026

Author - Melane Sampson

Dr. Ingrid Müller joins Evotec as COO

FDA grants Arbutus fast track designation for imdusiran in cHBV

Stereotaxis to acquire Robocath

MHRA clears Poolbeg for cancer immunotherapy trial

Prelude appoints Dr. Charles Morris as CMO

SIR highlights Profound’s CAPTAIN study results showing faster recovery with TULSA v robotic prostate surgery

Nature Medicine publishes Actuate’s data from trial of elraglusib + chemo in mPC

Cellectar enrolls first patient in Phase 1b study of CLR 125 targeting TNBC

MAIA Biotechnology aiming to extend lives through new cancer treatment class with telomere-targeting agent

Firefly builds world’s first 200,000+ EEG/ERP brain scan depository

Subscribe